scholarly journals Anxiety enhances pain in a model of osteoarthritis and is associated with altered endogenous opioid function and reduced opioid analgesia

PAIN Reports ◽  
2021 ◽  
Vol 6 (4) ◽  
pp. e956
Author(s):  
Amanda Lillywhite ◽  
Stephen G. Woodhams ◽  
Sara V. Gonçalves ◽  
David J.G. Watson ◽  
Li Li ◽  
...  
1997 ◽  
Vol 20 (3) ◽  
pp. 465-466
Author(s):  
Christoph Stein ◽  
Michael Schäfer

dickenson briefly mentions that peripheral opioid receptors somehow become active following inflammation and that the appearance of endogenous opioid peptides at the injury site may be related to immune cell proliferation. Recent findings elucidate the underlying mechanisms in more detail and provide an incentive for the development of a novel generation of analgesics devoid of typical central opioid side effects.


Neuropeptides ◽  
1985 ◽  
Vol 5 (4-6) ◽  
pp. 411-414 ◽  
Author(s):  
Kenneth D. Carr ◽  
Jacob M. Hiller ◽  
Eric J. Simon

Pain ◽  
2017 ◽  
Vol 158 (3) ◽  
pp. 391-399 ◽  
Author(s):  
John W. Burns ◽  
Stephen Bruehl ◽  
Christopher R. France ◽  
Erik Schuster ◽  
Daria Orlowska ◽  
...  

2017 ◽  
Vol 114 (31) ◽  
pp. 8396-8401 ◽  
Author(s):  
Miguel A. Tejada ◽  
Angeles Montilla-García ◽  
Shane J. Cronin ◽  
Domagoj Cikes ◽  
Cristina Sánchez-Fernández ◽  
...  

Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biological brake to opioid drug-induced analgesia. The pathophysiological role of this process is unknown. We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice. The selective sigma-1 antagonists BD-1063 and S1RA abolished mechanical and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation. Sigma-1–mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr–Gly–Gly–Phe at the N terminus of most endogenous opioid peptides (EOPs). Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody. The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate. These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation. In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.


2017 ◽  
Vol 14 (1) ◽  
Author(s):  
Uta Baddack-Werncke ◽  
Melanie Busch-Dienstfertig ◽  
Sara González-Rodríguez ◽  
Santhosh Chandar Maddila ◽  
Jenny Grobe ◽  
...  

Pain ◽  
2010 ◽  
Vol 148 (1) ◽  
pp. 167-171 ◽  
Author(s):  
Stephen Bruehl ◽  
Ok Y. Chung ◽  
Melissa Chont

2020 ◽  
Vol 16 (1) ◽  
pp. 67-72
Author(s):  
Alan R. Gintzler, PhD ◽  
Nai-Jiang Liu, MD, PhD

Objective: To review evidence demonstrating efficacy and feasibility of harnessing the activity of endogenous opioid analgesic systems for pain management.Methods: The authors sought to summarize a wealth of data that establish proof of concept that the analgesic activity of endogenous opioids can be exploited to clinically benefit from the enormous pain-relieving abilities of these peptides without contributing to the current crisis of death by synthetic opioid overdose.Results: There is a plethora of studies demonstrating that not only can endogenous opioids mediate placebo-induced antinociception but they are also active in modulating clinical pain. Earlier studies convincingly demonstrate the effectiveness of psychological strategies to coopt endogenous opioid analgesic systems to produce pain relief. The challenge is to define pharmacological targets for activating endogenous opioid analgesia reliably in a clinical setting. Based on insights gleaned from mechanisms underlying the ebb and flow of analgesic responsiveness to the spinal application of endomorphin 2, multiple signaling proteins were identified that activate endogenous spinal opioid analgesia. Notably, this was achieved in the absence of any exogenous synthetic opioid.Conclusions: Utilization of drugs that harness endogenous opioid antinociception in accordance with varying physiological states represents a novel approach for effective pain management while mitigating the present epidemic of death by synthetic opioid overdose.


Sign in / Sign up

Export Citation Format

Share Document